COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN COLOMBIA

被引：0
|
作者：
Lacey, M. [1 ]
Brouillette, M. [1 ]
Karpf, E. [2 ]
Lenhart, G. [1 ]
Barbeau, M. [3 ]
Russell, M. [1 ]
机构：
[1] Truven Hlth Analyt, Cambridge, MA USA
[2] Novartis Colombia, Bogota, Colombia
[3] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1218
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV72
引用
收藏
页码：A613 / A613
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Mariano A. Giorgi
    Carlos P. Boissonnet
    Paula Soledad Luque
    Jimena Piastrella
    Carlos Porley
    Fernanda Ditata
    Sergio Volman
    Health Economics Review, 13
  • [32] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Giorgi, Mariano A.
    Boissonnet, Carlos P.
    Luque, Paula Soledad
    Piastrella, Jimena
    Porley, Carlos
    Ditata, Fernanda
    Volman, Sergio
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [33] Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction
    King, Jordan
    Bress, Adam
    Bellows, Brandon
    ANNALS OF INTERNAL MEDICINE, 2017, 166 (08) : 606 - 607
  • [34] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    CIRCULATION, 2022, 146
  • [35] Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1148 - 1149
  • [36] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Claggett, Brian
    Chan, Wing W.
    Deschaseaux-Voinet, Celine
    Turner, Stuart J.
    Rouleau, Jean L.
    Zile, Michael R.
    McMurray, John J. V.
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2016, 1 (06) : 666 - 672
  • [37] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS IN INDIAN HEALTHCARE SETTING
    Gokhale, S.
    Partha, G.
    Proudfoot, C.
    Anand, S.
    VALUE IN HEALTH, 2022, 25 (01) : S115 - S115
  • [38] THE COST EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN KOREA
    Lee, J.
    Ko, S.
    VALUE IN HEALTH, 2017, 20 (09) : A617 - A618
  • [39] REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Afonso-Silva, M.
    Laires, P. A.
    VALUE IN HEALTH, 2019, 22 : S545 - S545
  • [40] Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Velazquez, Eric J.
    Morrow, David A.
    Braunwald, Eugene
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2020, 5 (11) : 1236 - 1244
12345